The Effectiveness of P2Y12 Receptor Antagonist Therapy is Strongly Determined by Endothelial Mediators of Platelet Function

被引：0
|
作者：
Knowles, Rebecca B.
Chan, Melissa V.
Armstrong, Paul C.
Shih, Chih-Chin
Hayman, Melissa A.
Vojnovic, Ivana
Tucker, Arthur T.
Timmis, Adam D.
Warner, Timothy D.
机构：
来源：
CIRCULATION | 2014年 / 130卷
关键词：
Antiplatelet drugs; Endothelial function; Thienopyridine; Nitric oxide; Prostacyclin;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
18581
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function
    Judge, Heather M.
    Buckland, Robert J.
    Sugidachi, Atsuhiro
    Jakubowski, Joseph A.
    Storey, Robert F.
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (06) : 1210 - 1217
  • [22] Progress in Platelet Blockers: The Target is the P2Y12 Receptor
    Patel, Prakash A.
    Lane, Bernard
    Augoustides, John G. T.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2013, 27 (03) : 620 - 624
  • [23] Monitoring platelet inhibition induced by P2Y12 receptor blockade:: A comparison of P2Y12 specific assays
    Angiolillo, Domiaick J.
    Desai, Bhaloo
    Hang, Yuan
    Charlton, Ronald
    Bernardo, Esther
    Shoemaker, Steven
    Zenni, Martin
    Guzman, Luis
    Gilmore, Paul
    Bass, Theodore A.
    Costa, Marco A.
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (8A): : 205M - 206M
  • [24] P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation
    Chan, Melissa V.
    Knowles, Rebecca B. M.
    Lundberg, Martina H.
    Tucker, Arthur T.
    Mohamed, Nura A.
    Kirkby, Nicholas S.
    Armstrong, Paul C. J.
    Mitchell, Jane A.
    Warner, Timothy D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (04) : 621 - 633
  • [25] Platelet function assays that assess response to P2Y12 antagonists vary widely in their sensitivities to low levels of P2Y12 receptor blockade
    Judge, H. M.
    Buckland, R. J.
    Sugidachi, A.
    Jakubowski, J. A.
    Storey, R. F.
    EUROPEAN HEART JOURNAL, 2008, 29 : 835 - 835
  • [26] AZD6140.: Antiplatelet therapy, P2Y12 (P2T) receptor antagonist
    Owen, R. T.
    Serradell, N.
    Bolos, J.
    DRUGS OF THE FUTURE, 2007, 32 (10) : 845 - 853
  • [27] Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor
    Douglass, James G.
    Patel, Roshni I.
    Yerxa, Benjamin R.
    Shaver, Sammy R.
    Watson, Paul S.
    Bednarski, Krzysztof
    Plourde, Robert
    Redick, Catherine C.
    Brubaker, Kurt
    Jones, Arthur C.
    Boyer, Jose L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (04) : 1007 - 1025
  • [28] Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist
    Anderson, Shawn D.
    Shah, Niren K.
    Yim, Juwon
    Epstein, Benjamin J.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (03) : 524 - 537
  • [29] Do we need a new P2Y12 receptor antagonist?
    Hulot, Jean-Sebastien
    Montalescot, Gilles
    EUROPEAN HEART JOURNAL, 2020, 41 (33) : 3141 - 3143
  • [30] Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist
    Ahn, Young Ha
    Lee, Joo-Youn
    Park, Hee Dong
    Kim, Tae Hun
    Park, Min Chul
    Choi, Gildon
    Kim, Sunghoon
    MOLECULES, 2016, 21 (09)
12345